Actionnariat et activité des initiés pour Aclaris Therapeutics, Inc. (ACRS): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $5.32 |
| Capitalisation | $743M |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $30.2M | $208.9M | $57.0M | $34.2M | $22.1M | $27.3M | $45.3M | $39.9M | $24.6M | $20.0M |
| Placements à Court Terme | $107.1M | 0 | $111.0M | $39.1M | $32.1M | $164.1M | $172.3M | $79.2M | $89.0M | $70.8M |
| Créances | 0 | $481000 | $563000 | $704000 | $772000 | $623000 | $484000 | $298000 | $318000 | $5.6M |
| Stocks | 0 | -$6.4M | $791000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $174.1M | $208.9M | $179.5M | $83.8M | $57.5M | $205.0M | $231.6M | $128.9M | $126.0M | $151.4M |
| Immobilisations Corporelles | $481000 | $2.2M | $4.3M | $2.5M | $1.7M | $1.3M | $1.1M | $1.6M | $1.0M | 0 |
| Goodwill | 0 | $18.5M | $18.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | $7.3M | $73.0M | $7.2M | $7.1M | $7.0M | $7.0M | $269000 | 0 | 0 |
| Actifs Totaux | $176.1M | $243.5M | $275.6M | $98.3M | $70.8M | $251.2M | $254.6M | $197.4M | $220.3M | $160.5M |
| Dettes Fournisseurs | $2.8M | $7.8M | $11.7M | $9.9M | $5.3M | $10.0M | $10.4M | $8.9M | $4.7M | $13.2M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $551000 |
| Passifs Courants | $6.2M | $12.8M | $27.3M | $22.4M | $14.9M | $22.9M | $21.9M | $31.0M | $31.6M | $28.6M |
| Dette à Long Terme | 0 | 0 | $29.9M | 0 | $10.7M | 0 | 0 | 0 | 0 | 0 |
| Passifs Totaux | $6.6M | $18.2M | $60.4M | $28.4M | $33.1M | $53.9M | $57.0M | $40.2M | $64.8M | $57.4M |
| Réserves | -$90.9M | -$159.4M | -$292.2M | -$453.5M | -$504.5M | -$595.4M | -$682.3M | -$770.8M | -$902.9M | -$967.8M |
| Capitaux Propres | $169.5M | $225.3M | $215.1M | $69.9M | $37.6M | $197.3M | $197.6M | $157.2M | $155.6M | $103.1M |
| Dette Totale | 0 | $142000 | $30.5M | $637000 | $11.3M | $693000 | $684000 | $426000 | 0 | $2.1M |
| Dette Nette | -$174.1M | -$208.7M | -$137.5M | -$72.6M | -$42.9M | -$190.7M | -$216.9M | -$118.7M | -$113.6M | -$88.6M |
| Fonds de Roulement | $167.9M | $196.1M | $152.2M | $61.4M | $42.6M | $182.1M | $209.6M | $97.9M | $94.4M | $122.7M |
Santé financière
| Dette / Capitaux propres | 0.00 |
| Ratio de liquidité | 3.46 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -5.19 |
Rentabilité
| Rentabilité des capitaux propres | -61.65% |
| Rentabilité du capital investi | -56.99% |
| Rentabilité des actifs | -42.15% |
| Marge brute | 95.61% |
| Marge opérationnelle | -1050.16% |
| Marge nette | -921.50% |
Entreprises liées: ALLO · BIOA · CABA · EDIT · MASS · MDXH · NEO
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de ACRS: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions